CAR T cell therapy / Mnemo Therap, Curie Institute, Memorial Sloan-Kettering Cancer Center - LARVOL DELTA

Non-Relapse Mortality after CAR T-Cell therapy for Large B-Cell Lymphoma: A LYSA Study from the DESCAR-T Registry. (PubMed, Blood Adv) - "We report on 957 patients who received standard-of-care axicabtagene ciloleucel (n = 598) or tisagenlecleucel (n = 359) between July 2018 and April 2022, in 27 French centers. In multivariate analysis, both diabetes and elevated ferritin at lymphodepletion were associated with an increased risk of overall NRM. Our results may help physicians in patient's selection and management in order to reduce the NRM after CAR T-cell therapy."

CAR T-Cell Therapy • Journal • Cardiovascular • Cerebral Hemorrhage • Diabetes • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Metabolic Disorders • Non-Hodgkin’s Lymphoma • Novel Coronavirus Disease • Oncology

Anti-CD19 CAR T-Cell Therapy for Patients with Richter Syndrome: A Lysa Study from the Descar-T Registry (ASH 2022) - "Indeed, chemoimmunotherapy regimens used in de novo DLBCL failed to induce a significant complete remission rate (CRR) (R-CHOP, 7%; ofatumumab-CHOP, 27%) (Langerbeins et al., AJH 2014; Eyre et al., BJH 2016). CD19-targeted chimeric antigenic receptor (CAR) T-cell therapy such as axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) have been transformative for patients with relapsed/refractory DLBCL...Seven (58%) patients received chemo-immunotherapy, 7 (58%) had been exposed to ibrutinib including 5 (42%) to both ibrutinib and venetoclax...Tocilizumab was administered to 9 (75%) patients...Frequency of CAR T-cell-specific adverse events was in the range of what is observed in de novo DLBCL while severity appeared higher (Schuster et al., NEJM 2019; Neelapu et al., NEJM 2017). Larger cohort with longer follow-up and prospective trials are warranted to confirm these observations."

CAR T-Cell Therapy • Clinical • IO biomarker • Anemia • Chronic Lymphocytic Leukemia • Critical care • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Infectious Disease • Inflammation • Leukemia • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Richter's Syndrome • Thrombocytopenia • CD19 • IGH • TP53

AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION FOR MARGINAL ZONE LYMPHOMAS – MULTICENTER ANALYSIS BY THE POLISH LYMPHOMA RESEARCH GROUP (EBMT 2023) - "All three entities, although reorganized, were retained in the 5th edition of the WHO classification.Despite significant progress in the treatment of indolent lymphomas, treatment options for MZL are still limited, including CAR-T-cell therapy showing only modest efficacy... Auto-HCT can still be considered a valuable option for carefully selected patients with MZL or t-MZL, allowing for long-term disease control in a significant proportion of patients, including patients with POD24. The risk of SPM is within the range reported for auto-HCT."

Clinical • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Transplantation